Emergent BioSolutions Reports Financial Results For First Quarter 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- BuzzFeed cuts 35% of workforce in restructuring move
Emergent BioSolutions (EBS) Tops Q1 EPS by 6c
April 28, 2022 4:36 PM EDTEmergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.18, $0.06 better than the analyst estimate of $0.12. Revenue for the quarter came in at $307.5 million versus the consensus estimate of $283.57 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
... More